Table 4 Characteristics of Patients who Developed Metastatic/Recurrent Disease.
Stage | Grade | ER/PR/HER2 status | Systemic therapy (prior to ZOL) | Baseline DTC/mL | M12 DTC/mL | M24 DTC/mL | Baseline CTC/mL | M6 CTC/mL | M12 CTC/mL | M18 CTC/mL | M24 CTC/mL | Time to recurrence from diagnosis (months) | Site of recurrence | Time to Overall Survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
III | 2 | TNBC | AC/T | 30.9 | – | – | 8.6 | – | – | – | – | 5.5 | CNS | 8.1 |
II | 2 | TNBC | AC/T | 332.9 | – | – | 0 | – | – | – | – | 11.5 | CNS | 24.8 |
III | 2 | TNBC | AC/T | 30.1 | – | 0.9 | 0.2 | – | – | – | 12 | Visceral + skeletal | 21.8 | |
I | 3 | TNBC | AC/T | 14.2 | – | – | 2.4 | – | – | – | – | 17.5 | Visceral + skeletal | 34.5 |
II | 3 | TNBC | AC/T | 32 | – | – | 0 | 0 | – | – | – | 21 | CNS | 22.9 |
III | 2 | ER + /PR-/HER2 + | AC/T + exemestane + trastuzumab | 8.5 | 6.9 | 168.6 | 0.5 | 0.6 | 0.3 | 39 | Visceral | 71.4 | ||
III | 3 | TNBC | AC/T | 13.3 | – | 0.1 | – | 1 | – | 43 | Local recurrence | Alive | ||
II | 3 | ER + /PR + /HER2 + | AC/T + trastuzumab | 5 | 0 | 3.3 | 0.2 | 0 | 0 | – | 0.1 | 79 | Local recurrence | Alive |
III | 2 | ER + /PR + /HER2- | AC/T | 22.5 | 3.1 | – | 0 | 0.1 | – | – | – | 111 | Pleural effusion | Alive |
